Signal transducers and activators of transcription 3 function in lung cancer
- PMID: 24135245
- DOI: 10.4103/0973-1482.119100
Signal transducers and activators of transcription 3 function in lung cancer
Abstract
Constitutively activation of signal transducers and activators of transcription 3 (STAT3) proteins are involved in multiple aberrant signaling pathway-oncogenic pathways, including pathways regulating tumor cell survival. STAT3 is one of the second messengers in the Janus activated family kinases/STAT signaling pathway and is regulated by many different factors involving tumorigenesis. Given that the activation of STAT3 is observed in nearly 50% of Lung cancers and more and more researches regarding STAT3 in tumors, here in, we reviewed the contribution of STAT3 to lung cancer growth and progression and then the context in which positive and negative regulation of STAT activation leading to cell competition provides a mechanism for therapeutic intervention for specific cancers is discussed.
Similar articles
-
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.Clin Cancer Res. 2005 Dec 1;11(23):8288-94. doi: 10.1158/1078-0432.CCR-05-0827. Clin Cancer Res. 2005. PMID: 16322287
-
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Cancer Res. 2006 Mar 15;66(6):3162-8. doi: 10.1158/0008-5472.CAN-05-3757. Cancer Res. 2006. PMID: 16540667
-
Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway.BMC Cancer. 2019 May 15;19(1):454. doi: 10.1186/s12885-019-5665-6. BMC Cancer. 2019. PMID: 31092229 Free PMC article.
-
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.Clin Cancer Res. 2002 Apr;8(4):945-54. Clin Cancer Res. 2002. PMID: 11948098 Review.
-
Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.Curr Cancer Drug Targets. 2004 Dec;4(8):637-51. doi: 10.2174/1568009043332736. Curr Cancer Drug Targets. 2004. PMID: 15578920 Review.
Cited by
-
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.Am J Cancer Res. 2014 Sep 6;4(5):411-35. eCollection 2014. Am J Cancer Res. 2014. PMID: 25232485 Free PMC article. Review.
-
MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer.Cancer Genomics Proteomics. 2019 Mar-Apr;16(2):99-119. doi: 10.21873/cgp.20116. Cancer Genomics Proteomics. 2019. PMID: 30850362 Free PMC article. Review.
-
Expression profile and prognostic values of STAT family members in non-small cell lung cancer.Am J Transl Res. 2019 Aug 15;11(8):4866-4880. eCollection 2019. Am J Transl Res. 2019. PMID: 31497205 Free PMC article.
-
Steroidal Saponins: Naturally Occurring Compounds as Inhibitors of the Hallmarks of Cancer.Cancers (Basel). 2023 Jul 31;15(15):3900. doi: 10.3390/cancers15153900. Cancers (Basel). 2023. PMID: 37568716 Free PMC article. Review.
-
Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.Mol Cell Biochem. 2019 Jun;456(1-2):145-156. doi: 10.1007/s11010-019-03500-3. Epub 2019 Jan 25. Mol Cell Biochem. 2019. PMID: 30684134
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous